title: White matter integrity is associated with treatment outcome measures in cocaine dependence.
abstract: Cocaine dependence is associated with white matter impairments that may compromise cognitive function and hence drug users' abilities to engage in and benefit from treatment. The main aim of this study was to assess whether white matter integrity correlates with treatment outcome measures in cocaine dependence. Diffusion tensor imaging (DTI) was used to assess the white matter (WM) of 16 treatment-seeking cocaine-dependent patients before 8 weeks of therapy. The measures for treatment outcome were longest self-reported duration of continuous cocaine abstinence, percent of urine screens negative for cocaine, and duration (weeks) of treatment retention. Correlations between treatment outcome measures and DTI parameters (fractional anisotropy (FA), longitudinal eigenvalue (lambda(1)), perpendicular eigenvalue (lambda(T)), and mean diffusivity (MD)) were analyzed. Longest self-reported abstinence from cocaine and percent of cocaine-negative urine samples during treatment positively correlated with FA values and negatively correlated with lambda(1), lambda(T), and MD values across extensive brain regions including the corpus callosum, frontal, parietal, temporal, and occipital lobes, and cerebellum. The findings of an association between better WM integrity at treatment onset and longer abstinence suggest that strategies for improving WM integrity warrant consideration in developing new interventions for cocaine dependence.
authors.affiliation: Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, CT 06519, USA.
authors.forename: Jiansong
authors.initials: J
authors.lastname: Xu
authors.forename: Elise E
authors.initials: EE
authors.lastname: DeVito
authors.forename: Patrick D
authors.initials: PD
authors.lastname: Worhunsky
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Carroll
authors.forename: Bruce J
authors.initials: BJ
authors.lastname: Rounsaville
authors.forename: Marc N
authors.initials: MN
authors.lastname: Potenza
mesh_terms: D000328:Adult; D016880:Anisotropy; D001921:Brain / Q000473:pathology*; D001931:Brain Mapping; D019970:Cocaine-Related Disorders / Q000188:drug therapy / Q000473:pathology* / Q000523:psychology / Q000652:urine; D038524:Diffusion Magnetic Resonance Imaging / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009413:Nerve Fibers, Myelinated / Q000473:pathology*; D017063:Outcome Assessment, Health Care; D016032:Randomized Controlled Trials as Topic; D012649:Self Concept; D013223:Statistics as Topic
references.citation: Neurotherapeutics. 2007 Jul;4(3):316-29
references.pmid: 17599699
references.citation: Exp Clin Psychopharmacol. 2008 Dec;16(6):484-97
references.pmid: 19086769
references.citation: Biol Psychiatry. 2009 Jan 15;65(2):122-8
references.pmid: 18814867
references.citation: Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003023
references.pmid: 17636713
references.citation: Nebr Symp Motiv. 2004;50:1-18
references.pmid: 15160636
references.citation: Addiction. 2006 Sep;101 Suppl 1:23-30
references.pmid: 16930158
references.citation: J Addict Dis. 2004;23(2):109-22
references.pmid: 15132346
references.citation: Biol Psychiatry. 2002 Jun 1;51(11):890-5
references.pmid: 12022962
references.citation: Biol Psychiatry. 2008 Oct 15;64(8):730-3
references.pmid: 18620337
references.citation: Neuroimage. 2006 Sep;32(3):1090-9
references.pmid: 16765064
references.citation: Psychiatry Res. 2007 Apr 15;154(3):253-8
references.pmid: 17321725
references.citation: Am J Psychiatry. 2001 Aug;158(8):1191-8
references.pmid: 11481148
references.citation: Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3137-46
references.pmid: 18640920
references.citation: Int J Neuropsychopharmacol. 2007 Dec;10(6):765-75
references.pmid: 17147837
references.citation: Subst Use Misuse. 2011;46(1):23-34
references.pmid: 21190403
references.citation: Am J Addict. 2006 Nov-Dec;15(6):434-9
references.pmid: 17182445
references.citation: Drug Alcohol Depend. 2008 Jan 1;92(1-3):164-72
references.pmid: 17904770
references.citation: J Subst Abuse Treat. 2007 Jan;32(1):41-52
references.pmid: 17175397
references.citation: Drug Alcohol Depend. 2009 Oct 1;104(3):262-7
references.pmid: 19595517
references.citation: Magn Reson Imaging. 2008 Jun;26(5):683-93
references.pmid: 18440747
references.citation: JAMA. 1998 Feb 4;279(5):376-80
references.pmid: 9459471
references.citation: Am J Psychiatry. 2007 Jan;164(1):4-6
references.pmid: 17202534
references.citation: Curr Opin Pharmacol. 2005 Feb;5(1):9-19
references.pmid: 15661620
references.citation: Biol Psychiatry. 2008 Dec 1;64(11):998-1004
references.pmid: 18635157
references.citation: J Consult Clin Psychol. 2000 Feb;68(1):134-44
references.pmid: 10710848
references.citation: Br J Radiol. 2004;77 Spec No 2:S167-75
references.pmid: 15677358
references.citation: Ann N Y Acad Sci. 2009 Jul;1169:385-94
references.pmid: 19673813
references.citation: Int J Addict. 1994 Apr;29(6):729-40
references.pmid: 8034382
references.citation: Neurosci Biobehav Rev. 2006;30(6):762-74
references.pmid: 16890990
references.citation: Neuroimage. 2007 Jan 1;34(1):127-36
references.pmid: 17070706
references.citation: Neuroimage. 2006 Jul 15;31(4):1487-505
references.pmid: 16624579
references.citation: Neuropsychopharmacology. 2005 Mar;30(3):610-7
references.pmid: 15637640
references.citation: Addict Behav. 1997 Mar-Apr;22(2):233-45
references.pmid: 9113217
references.citation: Neuroimage. 2008 Jul 1;41(3):1067-74
references.pmid: 18424082
references.citation: J Subst Abuse Treat. 2001 Dec;21(4):193-8
references.pmid: 11777668
references.citation: Drug Alcohol Depend. 2006 Feb 28;81(3):313-22
references.pmid: 16171953
references.citation: Arch Gen Psychiatry. 1999 Jun;56(6):507-14
references.pmid: 10359464
references.citation: Am J Drug Alcohol Abuse. 2007;33(6):777-89
references.pmid: 17994474
references.citation: Am J Psychiatry. 2008 Jul;165(7):881-8
references.pmid: 18450927
references.citation: Synapse. 1992 Jul;11(3):184-90
references.pmid: 1636149
references.citation: Biol Psychiatry. 2002 Apr 15;51(8):605-11
references.pmid: 11955460
references.citation: J Consult Clin Psychol. 1999 Feb;67(1):37-42
references.pmid: 10028207
references.citation: BioDrugs. 2007;21(4):259-67
references.pmid: 17628123
references.citation: J Subst Abuse Treat. 1992;9(3):199-213
references.pmid: 1334156
references.citation: Brain. 2008 Feb;131(Pt 2):559-72
references.pmid: 18083753
references.citation: Hum Brain Mapp. 2002 Jan;15(1):1-25
references.pmid: 11747097
references.citation: Psychopharmacology (Berl). 1999 Oct;146(4):373-90
references.pmid: 10550488
references.citation: Addict Behav. 2007 Dec;32(12):2819-36
references.pmid: 17543472
references.citation: Arch Gen Psychiatry. 2002 Jun;59(6):538-44
references.pmid: 12044196
references.citation: J Neurosci. 2008 Dec 24;28(52):14189-201
references.pmid: 19109501
references.citation: Am J Psychiatry. 2008 Feb;165(2):179-87
references.pmid: 18198270
references.citation: Annu Rev Psychol. 2008;59:29-53
references.pmid: 18154498
references.citation: Neuropsychopharmacology. 2008 Mar;33(4):827-36
references.pmid: 17568399
references.citation: J Neurosci. 2009 Mar 4;29(9):2805-13
references.pmid: 19261876
references.citation: Am J Psychiatry. 2005 Aug;162(8):1403-13
references.pmid: 16055761
references.citation: Neuroimage. 2002 Nov;17(3):1429-36
references.pmid: 12414282
references.citation: Psychiatry Res. 2010 Jan 30;181(1):57-63
references.pmid: 19959341